Texas is currently home to 4880 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
Recruiting
This is a Phase 2, single-site, single-arm open-label trial of zanidatamab in patients with early stage, low risk HER2+ BC. The primary objective is to determine the efficacy of zanidatamab for patients with early stage HER2/neu positive (HER2+) breast cancer (BC) as determined by pathologic complete response (pCR) .
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer, HER2-positive
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
Recruiting
This phase Ib trial is to find out the side effects and possible benefits of decitabine alone or given together with venetoclax, gilteritinib, enasidenib, or ivosidenib in treating patients with acute myeloid leukemia that is under control (remission). Chemotherapy drugs, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax may stop the growth of cancer cells by b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia
Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)
Recruiting
This is a prospective cohort study designed to define the impact of HIV infection and antiretroviral therapy (ART) on young adults with perinatal HIV infection (YAPHIV) as they transition into adulthood. A group of of perinatally exposed but uninfected young adults from a similar sociodemographic background and age distribution will be enrolled for comparison.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: HIV/AIDS
Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women
Recruiting
SMARTT will estimate the incidence of conditions and diagnoses potentially related to in utero exposure to antiretroviral therapy and/or exposure in the first two months of life among children born of HIV-infected mothers.
Gender:
ALL
Ages:
All
Trial Updated:
01/07/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Antiretroviral Toxicity
Evaluation of Hemostasis in Bleeding and Thrombotic Disorders
Recruiting
The objective of this study will be to assess the coagulation system in-vitro in a variety of bleeding and clotting disorders using the ROTEG analyzer and the thrombin generation assay.
Gender:
ALL
Ages:
Between 1 day and 98 years
Trial Updated:
01/07/2025
Locations: The Univerisity of Texas Health Science Center at Houston, Houston, Texas
Conditions: Blood Coagulation Disorders, Inherited, Thrombotic Disorder
Outcomes of Low-Risk Endometrial Cancer with Isolated Tumor Cells in the Sentinel Lymph Nodes: a Prospective, Multicenter, Cohort Study
Recruiting
This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.
Gender:
ALL
Ages:
All
Trial Updated:
01/06/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
Recruiting
The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: MD Anderson Cancer Center (Data Collection Only), Houston, Texas
Conditions: Advanced Melanoma
Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients
Recruiting
The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT). Primary Objective To determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors. Secondary Objectives: * To develop and validate a classifier based on pre-transplant immunological profi... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
01/06/2025
Locations: Cook Children's, Fort Worth, Texas
Conditions: Hematopoietic Cell Transplant, Solid Organ Transplant, Respiratory Viral Infection
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Recruiting
This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 (sebetralstat) in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
01/06/2025
Locations: KalVista Investigative Site, Dallas, Texas
Conditions: Hereditary Angioedema
Hearing Impairment, Strategies and Outcomes in VA Emergency Departments
Recruiting
HearVA involves six VA facility emergency departments (ED) over a 3-year intervention period. The first part of this study will test whether providing personal amplifiers to Veteran ED patients who self-report hearing difficulty is acceptable to these patients, can improve their hearing, enhance understanding of discharge instructions, and can reduce the risk of coming back to the ED in a short period of time (3 days and 30 days). The second part of the study will then identify whether ED staff... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
01/06/2025
Locations: VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas
Conditions: Hearing Loss, Emergency Service, Hospital Readmission
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Recruiting
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas
Conditions: Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
Recruiting
A prospective, single-arm, multi-center post-market surveillance study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Baylor Scott & White, Dallas, Texas
Conditions: Kidney Disease, End-Stage, End-stage Renal Disease, Arteriovenous Fistula